Karim Malek

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

David M. O’Malley, Ursula A. Matulonis, Michael J. Birrer et al. · Gynecologic Oncology · 2020 · 134 citations

Phase Ib Study, Medicine, Folate Receptor Alpha +10

Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity

Adeline Granzotto, Mohamed Amine Benadjaoud, Guillaume Vogin et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 119 citations

Atm Protein, Radiation Therapy, Radiobiology +12

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation

David C. Seldin, Jennifer J. Anderson, Vaishali Sanchorawala et al. · Blood · 2004 · 116 citations · Full text

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Ursula A. Matulonis, Michael J. Birrer, David M. O’Malley et al. · Clinical Cancer Research · 2018 · 78 citations

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Kathleen N. Moore, David M. O’Malley, Ignace Vergote et al. · Gynecologic Oncology · 2018 · 76 citations · Full text